Abstract:Objective: We investigated whether a selective beta 1 blocker, bisoprolol, improved chronic heart failure (HF) related to rheumatic heart disease (RHD) and atrial fibrillation (AF). Methods: We randomly assigned 88 chronic HF patients with RHD, a cardiothoracic ratio below 65%, and AF with a resting ventricular rate of 70 beats/minute or more for at least three months to either a treatment group or a control group. All patients received basic therapy: a diuretic, digoxin, an angio- tensin-conver ting enzyme (ACE)-inhibitor/angiotensin receptor blocker (ARB), or nitrates, depending on their blood pressure level and the presence of valvular lesions. All patients also received warfarin. Patients in the treatment group received bisoprolol. We then compared the short-term and long-term clinical and hemodynamic variables between the two groups. Results: Basic Characteristics. Thirty-three treated patients (75.0%) and 34 control patients (77.3%) completed the study. The follow-up period for both groups of patients was similar. There were no significant differences in age, sex, disease du- ration, the use of diuretics and ACE-inhibitors or ARBs, left ven- tricular (LV) end-diastolic dimension, or left atrial (LA) diam- eter. The LV ejection fraction (LVEF) for all patients was found to be higher than 40% in the two groups. Only three patients had an LVEF below 45%. The average maximum bisoprolol dose was 6.52 ± 2.7 mg/day in the treatment group; 54.5% of the patients tolerated at least 5 mg of bisoprolol once daily. Short-Term Results. The length of hospital stay was sig- nificantly shorter for the treated patients. At hospital dis- charge, these patients had a slower 24-hour average ventricu- lar rate and were able to walking farther over a period of six minutes, compared with the control group. Long-Term Results. During the follow-up period, the com- bined endpoint of chronic HF-related and thromboembolism- related death or hospitalization in the treated patients was significantly lower than that in the control patients. After six to 12 months, only the control patients had a higher 24-hour average ventricular rate, a worse New York Heart Association (NYHA) class, and a lower exercise capacity. In contrast, the treatment group showed improved NYHA class and exercise capacity as well as a lower 24-hour average ventricular rate, lower systolic blood pressure; and a significantly decreased LA diameter. However, no significant changes in the LVEF or LV end-diastolic dimension were noted in the two groups during follow-up. Summary: The data suggest that a selective beta1 blocker might improve NYHA class and exercise tolerance for patients with chronic HF related to RHD and AF. Furthermore, the advantage of these effects provided by this agent might be mediated by a reduction in ventricular rate and LA volume.

Effects of bisoprolol on HCN channel mRNA expression and intrinsic heart rate in sinoatrial node of rats with aorta level left-to-right shunt

BISOPROLOL INHIBITS SODIUM CURRENT IN VENTRICULAR MYOCYTES OF RATS WITH DIASTOLIC HEART FAILURE

Β1-Adrenergic Blocker Bisoprolol Reverses Down-Regulated Ion Channels in Sinoatrial Node of Heart Failure Rats

Effect Of Bisoprolol On Serca2a And Ncx1 Expression In The Ventricular Myocyte Of Rats With Volume Overload Heart Failure

Resting heart rate control and prognosis in coronary artery disease patients with hypertension previously treated with bisoprolol: a sub-group analysis of the BISO-CAD study.

Bisoprolol Regulates β1-adrenergic Signaling and Cardiac Function in Pressure Overloaded Chronic Heart Failure Rats

Bisoprolol reverse down-regulated Ito and Ik1 in left ventricle of rabbits with heart failure

Bisoprolol Reversed Small Conductance Calcium-Activated Potassium Channel (sk) Remodeling in A Volume-Overload Rat Model

Achievement of a Target Dose of Bisoprolol May Not Be a Preferred Option for Attenuating Pressure Overload-Induced Cardiac Hypertrophy and Fibrosis

Bisoprolol Reverses Down-Regulation of Potassium Channel Proteins in Ventricular Tissues of Rabbits with Heart Failure

Effects of bisoprolol on kaliuretic peptide,plasma renin activity and atrial natriuretic peptide in patients with chronic congestive heart failure

Short-Term and Long-Term Effects of Bisoprolol on Chronic Heart Failure Related to Rheumatic Heart Disease and Atrial Fibrillation

Effects of Bisoprolol on myeloperoxidase and high sensitivity C reactive protein in congestive heart failure

Regulation by Bisoprolol for Cardiac MicroRNA Expression in a Rat Volume-Overload Heart Failure Model

Effects of Recombinant Human Brain Natriuretic Peptide and Trimetazine on Ventricular Remodeling of Rat

Effects of metoprolol on phosphorylated connexin 43 expression in myocardial tissues and apoptosis of myocardial cells in heart failure rats

The Protective Effects of Bisoprolol on Diastolic Heart Failure are Related to Attenuation of Oxidative Stress

Downregulation of Neuronal Sodium Channel Subunits Nav1.1 and Nav1.6 in the Sinoatrial Node from Volume-Overloaded Heart Failure Rat

Effects of Captopril on Ito and Ik1 Channels of Volume Overloaded Heart Failure Rats

Effect of Bisoprolol on Atrial Structural Remodeling in Patients with Nonvalvular Persistent Atrial Fibrillation

Effect of Calcium-Sensing Receptor Inhibition on the Vulnerability of Ventricular Arrhythmia in a Rat Model of Chronic Heart Failure